Form of Underwriter’s Warrant AgreementS Warrant Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) A.G.P./ALLIANCE GLOBAL PARTNERS OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF A.G.P./ALLIANCE GLOBAL PARTNERS OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.
Development and Clinical Manufacturing Services AgreementServices Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;
GLOBAL MASTER SERVICES AGREEMENTGlobal Master Services Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
THIS GLOBAL MASTER SERVICES AGREEMENT is made on the date of the last signature (the “Effective Date”) by and between ALTASCIENCES COMPANY INC. (“CRO”) having its principal place of business at 575, boul. Armand-Frappier, Laval, Quebec, Canada, H7V 4B3, and its Affiliates, and XORTX Therapeutics Inc. (“Sponsor”), having its principal place of business at c/o Suite 4000, 421 – 7th Avenue, Calgary, T29 4K9 (each a “Party,” and collectively, the “Parties”).
CONSULTING AMENDING AGREEMENTConsulting Amending Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations
THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements contained herein, the parties hereto agree as follows:
CONSULTING SERVICES AGREEMENTConsulting Services Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
XORTX THERAPEUTICS INC., a corporation incorporated under the laws of the province of British Columbia and having its head office at 4000, 421 – 7th Avenue SW, Calgary, Alberta, Canada T2P 4K9 (hereinafter referred to as the “Company”)
SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Colorado
This SPONSORED RESEARCH AGREEMENT (“Agreement”) is effective this 27 day of May, 2021 (the “Effective Date”) and made by and between XORTX Therapeutics Inc. (“Sponsor”), having a principal place of business at Calgary, Alberta, Canada, and Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver, a public institution of higher education created under the Constitution and the law of the State of Colorado (“Institution”), having administrative offices at University of Colorado Denver, Office of Grants and Contracts, Mail Stop F428, Anschutz Medical Campus Bldg 500, W1124, 13001 E 17th Place, Aurora, CO 80045.
PATENT RIGHTS PURCHASE AGREEMENTPatent Rights Purchase Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
NOW THEREFORE, in consideration of the premises and the mutual covenants, terms, conditions and agreements contained herein, and other good and valuable consideration, the sufficiency of which are hereby acknowledged by the Parties, the Parties agree as follows.
THIS AGREEMENT is made as of the 1st Day of November, 2021.Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
XORTX Therapeutics Inc. a body corporate, incorporated under the laws of the Canada in the Province of Alberta and having an office in the city of Calgary, in the Province of Alberta, (hereinafter called the “CORPORATION”)
Combined Master Services AgreementCombined Master Services Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Delaware
CERTAIN INFORMATION (INDICATED BY [***]) HAS BEEN EXCLUDED FROM THE VERSION OF THIS DOCUMENT FILED AS AN EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Appendix E - Equity...Equity Agreement • May 3rd, 2022 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Florida
THIS EQUITY AGREEMENT (the “Agreement”) is made effective the 23rd day of June, 2014 by and between the University of Florida Research Foundation, Inc. (hereinafter called “UFRF”), a non-stock, nonprofit Florida corporation, and XORTX Pharma Corp (hereinafter called “Licensee” or the “Company”), a corporation organized and existing under the laws of Canada.
